Speaking of waiting for data, shares of CEL-SCI (AMEX:CVM) may be trading 62.14 % below their 52-week highs, and some say the firm’s share price or valuation does not look like it belongs to a Phase III firm with a new drug aiming to become a standard of care. Could it be that the bashers are once again under estimating the firm’s recent accomplishments- including the faster than expected Phase III roll-out